Annual SG&A
$32.04 M
+$4.72 M+17.26%
31 December 2023
Summary:
Monte Rosa Therapeutics annual selling, general & administrative expenses is currently $32.04 million, with the most recent change of +$4.72 million (+17.26%) on 31 December 2023. During the last 3 years, it has risen by +$28.03 million (+699.98%). GLUE annual SG&A is now at all-time high.GLUE Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$8.13 M
-$1.16 M-12.44%
30 September 2024
Summary:
Monte Rosa Therapeutics quarterly selling, general & administrative expenses is currently $8.13 million, with the most recent change of -$1.16 million (-12.44%) on 30 September 2024. Over the past year, it has dropped by -$534.00 thousand (-6.17%). GLUE quarterly SG&A is now -12.44% below its all-time high of $9.28 million, reached on 30 June 2024.GLUE Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.64 B
-$119.39 M-7.83%
30 September 2024
Summary:
Monte Rosa Therapeutics TTM selling, general & administrative expenses is currently -$1.64 billion, with the most recent change of -$119.39 million (-7.83%) on 30 September 2024. Over the past year, it has dropped by -$1.68 billion (-5248.40%). GLUE TTM SG&A is now -3319.38% below its all-time high of $34.66 million, reached on 30 June 2024.GLUE TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLUE Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +17.3% | -6.2% | -5248.4% |
| 3 y3 years | +700.0% | +71.0% | -10000.0% |
| 5 y5 years | - | - | - |
GLUE Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +700.0% | -12.4% | +71.0% | -475.2% | at low |
| 5 y | 5 years | at high | +4875.0% | -12.4% | +1600.2% | -3319.4% | at low |
| alltime | all time | at high | +4875.0% | -12.4% | +1600.2% | -3319.4% | at low |
Monte Rosa Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $8.13 M(-12.4%) | $34.12 M(-1.5%) |
| June 2024 | - | $9.28 M(+3.3%) | $34.66 M(+3.4%) |
| Mar 2024 | - | $8.98 M(+16.3%) | $33.52 M(+4.6%) |
| Dec 2023 | $32.04 M(+17.3%) | $7.73 M(-10.8%) | $32.04 M(+0.3%) |
| Sept 2023 | - | $8.66 M(+6.3%) | $31.93 M(+5.4%) |
| June 2023 | - | $8.14 M(+8.5%) | $30.29 M(+6.5%) |
| Mar 2023 | - | $7.50 M(-1.5%) | $28.44 M(+4.1%) |
| Dec 2022 | $27.32 M | $7.62 M(+8.6%) | $27.32 M(+9.5%) |
| Sept 2022 | - | $7.02 M(+11.5%) | $24.96 M(+10.0%) |
| June 2022 | - | $6.29 M(-1.4%) | $22.69 M(+14.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $6.39 M(+21.5%) | $19.88 M(+26.4%) |
| Dec 2021 | $15.73 M(+292.7%) | $5.26 M(+10.6%) | $15.73 M(+25.4%) |
| Sept 2021 | - | $4.75 M(+36.3%) | $12.54 M(+44.1%) |
| June 2021 | - | $3.49 M(+56.3%) | $8.70 M(+51.1%) |
| Mar 2021 | - | $2.23 M(+7.6%) | $5.76 M(+43.8%) |
| Dec 2020 | $4.00 M(+521.9%) | $2.07 M(+126.8%) | $4.01 M(+107.2%) |
| Sept 2020 | - | $914.00 K(+68.9%) | $1.93 M(+89.7%) |
| June 2020 | - | $541.00 K(+13.2%) | $1.02 M(+113.2%) |
| Mar 2020 | - | $478.00 K | $478.00 K |
| Dec 2019 | $644.00 K | - | - |
FAQ
- What is Monte Rosa Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual SG&A year-on-year change?
- What is Monte Rosa Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly SG&A year-on-year change?
- What is Monte Rosa Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics TTM SG&A year-on-year change?
What is Monte Rosa Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of GLUE is $32.04 M
What is the all time high annual SG&A for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual selling, general & administrative expenses is $32.04 M
What is Monte Rosa Therapeutics annual SG&A year-on-year change?
Over the past year, GLUE annual selling, general & administrative expenses has changed by +$4.72 M (+17.26%)
What is Monte Rosa Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of GLUE is $8.13 M
What is the all time high quarterly SG&A for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly selling, general & administrative expenses is $9.28 M
What is Monte Rosa Therapeutics quarterly SG&A year-on-year change?
Over the past year, GLUE quarterly selling, general & administrative expenses has changed by -$534.00 K (-6.17%)
What is Monte Rosa Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of GLUE is -$1.64 B
What is the all time high TTM SG&A for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high TTM selling, general & administrative expenses is $34.66 M
What is Monte Rosa Therapeutics TTM SG&A year-on-year change?
Over the past year, GLUE TTM selling, general & administrative expenses has changed by -$1.68 B (-5248.40%)